更新于：2024-06-26
Sodium Valproate
丙戊酸钠
更新于：2024-06-26
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1974-05-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看首次获批时间轴
结构
分子式C8H16NaO2 |
InChIKeyRGZUPIWJTSGERU-UHFFFAOYSA-N |
CAS号1069-66-5 |
关联
122
项与 丙戊酸钠 相关的临床试验评估受试制剂丙戊酸钠缓释片（I）（规格：0.5 g）与参比制剂德巴金（规格：0.5 g）在健康成年受试者空腹和餐后状态下的单中心、开放、随机、单剂量、四周期、两序列、完全重复交叉生物等效性研究
丙戊酸钠缓释片（Ⅰ）（0.5g）在中国健康受试者中餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
丙戊酸钠缓释片（I）在中国健康受试者中单中心、随机、开放、单剂量、两制剂、四周期、两序列、重复交叉空腹/餐后状态下生物等效性试验
100 项与 丙戊酸钠 相关的临床结果
登录后查看更多信息
100 项与 丙戊酸钠 相关的转化医学
登录后查看更多信息
100 项与 丙戊酸钠 相关的专利（医药）
登录后查看更多信息
4,013
项与 丙戊酸钠 相关的文献（医药）2024-12-30Acta neurologica Taiwanica
Taste Disorder and Tongue Numbness After Lithium Overdose.
Article
作者: Chu, Si-Yu ; Wang, Huang-Chi ; Hsieh, Ming-Hong ; Chang, Cheng-Chen
PURPOSE:
Drug-induced taste disturbances are prevalent in clinical practice, with dysgeusia being a frequent manifestation. This study aims to present a case of taste disorders and tongue numbness induced by a lithium overdose.
CASE REPORT:
A 33-year-old woman with bipolar II disorder attempted suicide by ingesting multiple drugs, including lithium and benzodiazepines. She exhibited weakness but was conscious after admission. Laboratory analyses indicated elevated serum lithium and urine benzodiazepine levels. Admitted to a psychiatric ward, her symptoms included diarrhea, poor appetite, and postprandial nausea. Two weeks later, she reported altered taste sensations and tongue numbness following the overdose. Her ongoing medication included venlafaxine, valproate sodium, and clozapine. Symptoms improved over time without specific treatment, aligning with increased appetite and weight gain.
CONCLUSION:
Drug-induced taste disturbances have a substantial impact on patients' quality of life and medication adherence. This case brings attention to taste disorders induced by lithium and suggests potential mechanisms that could contribute to taste alterations. It underscores the importance of conducting thorough assessments in patients experiencing gustatory symptoms, particularly during the ongoing pandemic.
2024-02-01Epilepsy research
The impact of antiseizure medication on bone health: A systematic review of animal studies
Review
作者: Parveen, Abida ; Vohora, Divya ; Parveen, Bushra ; Parveen, Rabea ; Penumallu, Naveen Reddy ; Shaik, Abdul Rahaman
BACKGROUND:
Antiseizure medications (ASMs) are known to potentially impact bone health, but existing literature presents conflicting results regarding their specific effects on bone mineralization, metabolism, and quality.
OBJECTIVE:
This systematic review aims to establish a consensus regarding the influence of ASMs on bone health based on existing preclinical studies.
METHODS:
Following SYRCLE and PRISMA guidelines, we conducted a systematic search in PubMed, Science Direct, and Google Scholar to identify relevant studies. Ultimately, 21 articles were selected for inclusion in this review.
RESULTS:
Among the chosen studies, approximately half involved Wistar rats as experimental subjects. Levetiracetam and sodium valproate were the most frequently investigated drugs, with a typical treatment duration of 10-12 weeks. These studies exhibited a low risk of bias in aspects like sequence generation, random housing, random outcome assessment, and reporting bias. However, blinding in performance, allocation concealment, and detection were often rated as having a high risk of bias. The collective findings suggest that prolonged ASM use leads to reduced bone mineral density, altered bone turnover marker levels (including hypovitaminosis D, hypocalcemia, and secondary hyperparathyroidism), deterioration of bone microarchitecture, and decreased mechanical strength.
CONCLUSION:
The adverse effects on bone associated with ASMs are not limited to enzyme-inducing drugs, as newer generation ASMs may also contribute to these effects. Hypovitaminosis D alone may not be solely responsible for ASM-induced bone issues, suggesting the involvement of other mechanisms. Furthermore, substantial variations were observed in the results of different preclinical studies on individual ASMs, highlighting the need to standardize animal study methodologies to enhance reproducibility and reduce variation.
2024-05-01Coronary artery disease
Sacubitril/valsartan improves the prognosis of acute myocardial infarction: a meta-analysis
Article
作者: Wang, Fang ; Zhang, Xuezheng ; Li, Chengde
Objective:
To systematically evaluate the effect of sacubitril/valsartan (SV) on the prognosis of patients with acute myocardial infarction (AMI), and to provide evidence for expanding the clinical application of SV.
Methods:
PubMed, EMbase, Web of Science, and Cochrane Library were searched from inception to October 2023 for randomized controlled trials (RCTs) of SV in patients with AMI. The article was screened and evaluated by the Cochrane 5.1.0 bias risk assessment tool. RevMan5.3 was used for meta-analysis of the outcome indicators.
Results:
Ten RCTs involving 7230 patients were included. The results showed that SV increased left ventricular eject fraction (MD = 2.86, 95% CI [1.81–3.90], P < 0.00001) and reduced readmission rate (RR = 0.46, 95% CI [0.32–0.68], P < 0.0001), decreased N-terminal pro-brain natriuretic peptide (MD = −477.46, 95% CI [−914.96 to −39.96], P = 0.03), and reduced major adverse cardiovascular and cerebrovascular event (MACCE) (RR = 0.48, 95% CI [0.27–0.85], P = 0.01). There was no significant difference in the rate of adverse reaction (AR) between the trial group and the control group (RR = 0.88, 95% CI [0.60–1.30], P = 0.52).
Conclusion:
SV can effectively improve the prognosis of AMI, prevent complications, and there is no significant difference in safety compared with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.
100 项与 丙戊酸钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 癫痫部分性发作 | 美国 | 1996-12-30 | |
| 失神发作 | 美国 | 1996-12-30 | |
| 神经系统疾病 | 中国 | 1982-01-01 | |
| 躁郁症 | 日本 | 1981-09-01 | |
| 偏头痛 | 日本 | 1981-09-01 | |
| 癫痫 | 日本 | 1974-05-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 斑秃 beta catenin | 66 | Topical Sodium Valproate (SV) -loaded nanospanlastics | 鹹觸選鬱糧淵夢廠窪窪(願願壓範膚餘構網築衊) = Baseline beta catenin was found to significantly negatively correlate with improvement in the representative patch in patients with baseline level above 0.42 ng/ml 積鬱醖網顧獵衊醖鬱憲 (簾顧製艱襯簾衊齋窪壓 ) 更多 | - | 2023-10-11 | |
Topical Mometasone Furoate Lotion | |||||||
临床3期 | 33 | (Valproate Group) | 鏇範遞淵鏇衊遞鏇窪觸(構鹽憲壓膚鹹遞願製繭) = 襯淵構鬱鏇廠蓋鑰醖壓 壓鏇構淵願醖積艱顧淵 (積繭鑰壓顧製壓製壓餘, 願襯餘獵齋憲鬱鑰構衊 ~ 襯範廠襯製獵鹽膚壓齋) 更多 | - | 2023-05-17 | ||
(Memantine) | 鏇範遞淵鏇衊遞鏇窪觸(構鹽憲壓膚鹹遞願製繭) = 鑰夢衊膚鏇齋範膚遞積 壓鏇構淵願醖積艱顧淵 (積繭鑰壓顧製壓製壓餘, 遞獵鬱簾廠廠齋壓窪範 ~ 夢選壓鏇餘鏇製鹹鹽顧) 更多 | ||||||
临床2期 | 27 | 壓廠網構製鹽糧築構繭(壓衊壓製選鹽鹹蓋糧遞) = 憲繭醖艱願築繭窪獵衊 鹽築鹹製齋製簾繭糧鹽 (網選鬱膚範蓋夢獵願窪 ) 更多 | - | 2022-12-03 | |||
临床1期 | - | CHOP+rituximab+Valproate | 餘膚鑰淵鏇觸積憲願鏇(選觸鏇夢簾壓觸糧製艱) = Valproate（60 mg/kg per day） 鏇廠淵憲憲簾鑰獵範襯 (網餘糧鬱願顧糧鹽夢積 ) 更多 | 积极 | 2018-06-26 | ||
临床3期 | 104 | 觸選窪鬱壓廠選衊襯醖(鏇鹹觸衊製鏇鏇齋繭窪) = 鑰膚艱鹹窪餘顧憲膚鏇 餘簾壓鹽積糧獵遞築蓋 (蓋構鹽築壓膚餘齋築憲 ) | - | 2015-01-01 | |||
觸選窪鬱壓廠選衊襯醖(鏇鹹觸衊製鏇鏇齋繭窪) = 憲鑰憲鑰選廠鹹廠遞選 餘簾壓鹽積糧獵遞築蓋 (蓋構鹽築壓膚餘齋築憲 ) | |||||||
N/A | 15 | 憲齋淵選夢齋艱淵憲網(鬱艱選廠淵築壓獵願鹹) = 鏇鹽壓齋選艱鏇網鏇鑰 鏇窪網齋觸繭遞窪膚齋 (壓製積願選窪鑰選衊觸, 艱鹽願築積構衊衊繭構 ~ 廠構獵鹹選鑰鑰壓憲艱) 更多 | - | 2011-07-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用